CG Invites Co., Ltd. Logo

CG Invites Co., Ltd.

A biopharmaceutical company specializing in digital genomics and personalized medicine.

083790 | KO

Overview

Corporate Details

ISIN(s):
KR7083790006
LEI:
Country:
South Korea
Address:
서울특별시 강서구 마곡중앙8로 38 마곡동, 강서구

Description

CG Invites Co., Ltd. is a biopharmaceutical company specializing in digital genomics and personalized medicine. The company's activities are focused on four main areas: genomics, personalized cancer vaccines, digital therapeutics, and the development of chemical and biological drugs. It utilizes Whole Genome Sequencing to support precision medicine initiatives and develops mRNA-based personalized cancer vaccines. The company also creates software-based medical interventions, known as digital therapeutics. Its drug development pipeline includes therapeutics for oncology and inflammatory diseases, such as Acelex for osteoarthritis, Ivaltinostat for pancreatic cancer, and Camrelizumab for immuno-oncology. The company's research approach is based on structural chemoproteomics and the integration of genomic data to develop targeted treatments.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
반기보고서 (2025.06)
Korean 1.8 MB
2025-08-14 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 34.7 KB
2025-08-08 00:00
[기재정정]사업보고서 (2024.12)
Korean 2.7 MB
2025-07-25 00:00
[기재정정]단일판매ㆍ공급계약체결
Korean 16.5 KB
2025-07-17 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.3 KB
2025-07-10 00:00
소송등의판결ㆍ결정 (신주발행 무효-취하)
Korean 5.3 KB
2025-07-10 00:00
소속부변경
Korean 3.6 KB
2025-07-02 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 38.0 KB
2025-07-01 00:00
[기재정정]단일판매ㆍ공급계약체결
Korean 14.1 KB
2025-07-01 00:00
소속부변경
Korean 3.6 KB
2025-06-05 00:00
주식등의대량보유상황보고서(일반)
Korean 134.5 KB
2025-06-05 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 28.6 KB
2025-06-05 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 29.4 KB
2025-06-05 00:00
기업설명회(IR)개최
Korean 6.8 KB
2025-05-14 00:00
분기보고서 (2025.03)
Korean 1.8 MB

Automate Your Workflow. Get a real-time feed of all CG Invites Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CG Invites Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for CG Invites Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Evoke Pharma Inc Logo
A specialty pharma company developing drugs for gastrointestinal (GI) diseases.
United States of America
EVOK
Evolus, Inc. Logo
A performance beauty company developing neurotoxins and dermal fillers.
United States of America
EOLS
EXACT Therapeutics AS Logo
Clinical-stage biopharma using ultrasound to amplify the effect of co-administered drugs.
Norway
EXTX
EXELIXIS, INC. Logo
Oncology-focused biotech that discovers, develops, and commercializes cancer therapies.
United States of America
EXEL
ExpreS2ion Biotech Holding AB Logo
A clinical-stage biotech company developing vaccines for cancer and infectious diseases.
Sweden
EXPRS2
EyePoint Pharmaceuticals, Inc. Logo
Develops sustained drug delivery therapeutics for serious retinal diseases.
United States of America
EYPT
Faes Farma S.A. Logo
Researches, develops, and markets pharmaceuticals and animal nutrition products.
Spain
FAE
Fagron N.V. Logo
A global pharmaceutical compounding company focused on personalized medicine.
Belgium
FAGR
Farmak Logo
Researches, develops, and manufactures medicines for distribution in over 60 countries.
Ukraine
FARM
Farmsintez ao Logo
Develops and produces APIs and finished dosage forms; offers contract manufacturing.
Russian Federation
LIFE

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.